Taiwanese journal of obstetrics & gynecology · 2026
Frequency of mismatch repair deficiency for primary endometrial neuroendocrine carcinoma and its therapeutic outcome in Japan.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hiranuma Kengo, Hirayama Takashi, Ito Yosuke, Kaneda Hiroshi, Yamaguchi Maiko, Ozaki Rie, Terao Junna, Kawata Misato, Okumura Toshiyuki, Yoshida Emiko, Saeki Harumi, Fujino Kazunari, Terao Yasuhisa
Аннотация
OBJECTIVE: To investigate the frequency of mismatch repair (MMR) deficiency in primary endometrial neuroendocrine carcinoma (PENEC) and analyze its therapeutic outcomes in Japan.
MATERIALS AND METHODS: A multicenter retrospective study of 17 cases of PENEC diagnosed between 2011 and 2023 was conducted. MMR status was evaluated by immunohistochemistry, and clinical outcomes were assessed.
RESULTS: Among the 17 cases, 10 (58.8%) were diagnosed at advanced stages (stage III and Ⅳ). The median overall survival was 16 months, indicating extremely poor prognosis. MMR deficiency was observed in 41% of cases, a rate higher than that reported for other endometrial cancer subtypes.
CONCLUSION: PENEC demonstrates aggressive behavior and poor prognosis compared to other histological subtypes of endometrial cancer. The higher rate of MMR deficiency suggests that immune checkpoint inhibitors may serve as key components of initial treatment strategies, potentially contributing to improved outcomes for this rare and aggressive malignancy.
MATERIALS AND METHODS: A multicenter retrospective study of 17 cases of PENEC diagnosed between 2011 and 2023 was conducted. MMR status was evaluated by immunohistochemistry, and clinical outcomes were assessed.
RESULTS: Among the 17 cases, 10 (58.8%) were diagnosed at advanced stages (stage III and Ⅳ). The median overall survival was 16 months, indicating extremely poor prognosis. MMR deficiency was observed in 41% of cases, a rate higher than that reported for other endometrial cancer subtypes.
CONCLUSION: PENEC demonstrates aggressive behavior and poor prognosis compared to other histological subtypes of endometrial cancer. The higher rate of MMR deficiency suggests that immune checkpoint inhibitors may serve as key components of initial treatment strategies, potentially contributing to improved outcomes for this rare and aggressive malignancy.